ReadCoor Names Dr. Thomas M. Grogan to its Board of Directors

OCTOBER 11, 2017

Cambridge, Mass. October 11, 2017 – (BUSINESS WIRE) – ReadCoor, Inc., a company reinventing omics and pathology with its panomic spatial sequencing platform, today announced the appointment of Thomas M. Grogan, M.D., to its Board of Directors. Dr. Gorgan is the renowned pathologist and founder of Ventana Medical Systems, a world leader and innovator of tissue-based diagnostic solutions for patients worldwide.

“We are thrilled to welcome Tom to the ReadCoor Board of Directors. He brings a remarkable track record of leadership experience in the areas of clinical care, global product development and innovation,” said Shawn Marcell, ReadCoor’s Chief Executive Officer and Chairman of the Board. “His insight and counsel will support the advancement of our Fluorescent in situ Sequencing platform.

Dr. Grogan is Professor Emeritus of Pathology at the University of Arizona College of Medicine, and a scientific advisor to Ventana Medical Systems and Roche Tissue Diagnostics. He is a founding member of the International Lymphoma Study Group, a group of scientists credited with the development of the clinical practice classifications set forth by the World Health Organization. He is also author of more than 250 articles on myeloma and lymphoma, and listed as an inventor on patents for automated immunohistochemistry (IHC) and in-situ hybridization (ISH).

“I am excited to join ReadCoor’s Board of Directors and look forward to working with the team to commercialize FISSEQ,” said Dr. Grogan. “ReadCoor has had an impressive first year of operation and I look forward to contributing to the organization’s momentum and the development of innovative research tools that could help deliver swifter results to patients.”

About Fluorescent in situ Sequencing (FISSEQ) 

FISSEQ is a spatial sequencing technology that reads and visualizes the three-dimensional coordinates of molecules of intact tissue, a capability that stands to revolutionize panomics and pathology. FISSEQ was developed in the Church Lab at Harvard University and the Wyss Institute for Biologically Inspired Engineering, and first published in Science in 2014 (Highly multiplexed three-dimensional subcellular transcriptome sequencing in situ). The platform has broad application in the areas of drug development, diagnostics, and machine learning.

About ReadCoor, Inc. 

ReadCoor is leading the next generation of omics by delivering the first panomic spatial sequencing platform to the global audience of researchers, clinicians, pharma and diagnostics companies, and ultimately patients. It is accomplishing this with Fluorescent in situSequencing (FISSEQ), a fundamental new technology, which simultaneously integrates high-throughput sequencing, and three-dimensional morphometric analysis. This uniquely powerful platform is expected to revolutionize the next phase in understanding the panomic landscape and introduce vast new opportunities for important and meaningful clinical insight.


ReadCoor, Inc.
Christine Lafontant